Because EGFR is mutated or overexpressed in a variety of human cancers, it has become a major prognostic marker and therapeutic target (Grandis and Sok, 2004; Herbst et al., 2004; Nicholson et al., 2001). The gene discussed is EGFR; the disease is cancer.